GMO Dialogues | Impacts of GLP-1 Receptor Agonists and SGLT-2 Inhibitor on CKD with Dr Frank Maddux

Dr. Frank Maddux discusses the potential impact of GLP-1 Receptor agonists and SGLT-2 Inhibitors on chronic kidney disease care.
Franklin W. Maddux is global chief medical officer for Fresenius Medical Care, overseeing the delivery of high-quality, value-based care for the world’s most expansive kidney care organization. His distinguished career encompasses more than three decades of experience as a physician, expert nephrologist, technology entrepreneur, and healthcare executive. Dr. Maddux joined Fresenius Medical Care’s North America region in 2009 after the company acquired Health IT Services Group, a leading electronic health record (EHR) software company, which he founded. He developed one of the first laboratory electronic data interchange programs for the US dialysis industry and later created one of the first web-based EHR solutions, now marketed under Acumen Physician Solutions. He previously served as chief medical officer and senior vice president for Specialty Care Services Group and is the former president of Virginia’s Danville Urologic Clinic, where he was a practicing nephrologist for nearly two decades. His writings have appeared in leading medical journals, and his pioneering healthcare information technology innovations are part of the permanent collection of the National Museum of American History at the Smithsonian Institution. An alumnus of Vanderbilt University, Dr. Maddux earned his medical degree from the School of Medicine at the University of North Carolina at Chapel Hill, where he holds a faculty appointment as clinical associate professor.